5-(3,5-二氯苯氧基)呋喃-2-羰酰氯 | 175277-07-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-(3,5-二氯苯氧基)呋喃-2-羰酰氯
• 英文名称: 5-(3,5-Dichloro-phenoxy)-furan-2-carbonyl chloride
• 英文别名: 5-(3,5-Dichlorophenoxy)furan-2-carbonyl chloride
• CAS: 175277-07-3
• 化学式: C₁₁H₅Cl₃O₃
• 分子量: 291.518
• InChiKey: YLENOTQUCQGWGX-UHFFFAOYSA-N

物化性质

• 熔点：
  60 °C
• 沸点：
  378.2±42.0 °C(Predicted)
• 密度：
  1.509±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  N-{3-[1-(6-aminohexyl)piperidin-4-yl]phenyl}isobutyramide 、 5-(3,5-二氯苯氧基)呋喃-2-羰酰氯 以 四氢呋喃 为溶剂， 生成 5-(3,5-Dichlorophenoxy)-N-(6-{4-[3-(isobutyrylamino)phenyl]-1-piperidinyl}hexyl)-2-furamide
  参考文献：
  名称：

  Substituted anilinic piperidines as MCH selective antagonists

  摘要：

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。

  公开号：

  US20070043080A1

文献信息

• [EN] PHOSPHATE/SULFATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN INTERACTING NIMA (PIN1)<br/>[FR] COMPOSES A BASE D'ESTERS DE SULFATE/PHOSPHATE ET COMPOSITIONS PHARMACEUTIQUES INHIBANT L'ACTIVITE DE NIMA INTERAGISSANT AVEC DES PROTEINES (PIN1)
  申请人：PFIZER

  公开号：WO2004087720A1

  公开（公告）日：2004-10-14

  Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.

  磷酸/硫酸酯化合物能够调节和/或抑制与蛋白质相互作用的NIMA（PIN1）的活性，以及包含此类化合物的药物组合物。本发明还涉及此类化合物和组合物的治疗或预防用途，以及通过施用有效量的此类化合物来治疗表现为高血压、不适当的细胞增殖、传染性疾病和神经退行性脑障碍的方法。
• Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1)
  申请人：Dagostino Eleanor

  公开号：US20050250742A1

  公开（公告）日：2005-11-10

  Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.

  磷酸/硫酸酯化合物能够调节和/或抑制与蛋白质相互作用的NIMA（PIN1）的活性，以及包含此类化合物的药物组合物。本发明还涉及此类化合物和组合物的治疗或预防用途，以及通过施用有效量的此类化合物来治疗表现为高血压、不适当的细胞增殖、感染性疾病和神经退行性脑障碍的方法。
• [EN] NOVEL DIAZABICYCLIC ARYL DERIVATIVES<br/>[FR] DERIVES ARYLE DIAZABICYCLIQUES
  申请人：NEUROSEARCH AS

  公开号：WO2004076453A1

  公开（公告）日：2004-09-10

  This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及新颖的二氮杂双环芳基衍生物，发现它们在尼古丁型乙酰胆碱受体上是胆碱能配体。由于它们的药理特性，该发明的化合物可能对与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩有关的疾病或疾病、内分泌疾病或疾病、神经退行性疾病或疾病、炎症、疼痛以及由于滥用化学物质而导致的戒断症状有用。
• 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
  申请人：Wyeth

  公开号：US20030045560A1

  公开（公告）日：2003-03-06

  This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: 1 Wherein: Ar is phenyl, naphthyl, furanyl, benzofuranyl, indolyl, pyrazolyl, oxazolyl, fluorenyl, phenylcycloalkane where the cycloalkane can be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and Ar can be optionally substituted by 1 to 3 groups selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, phenyl-(CH 2 ) 0-6 —, phenyl-(CH 2 ) 0-6 O—, C 3 -C 6 cycloalkyl, —(CH 2 )—C 3 -C 6 cycloalkyl, halogen, C 1 -C 3 perflouroalkyl and C 1 -C 3 perfluoroalkoxy where phenyl can be substituted with from 1 to 3 groups selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, phenyl, halogen, trifluoromethyl or trifluoromethoxy; R 1 is hydrogen, C 1 -C 6 alkyl or phenyl-(CH 2 ) 1-6 — where phenyl can be substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R 2 and R 3 are H, C 1 -C 6 alkyl, phenyl-(CH 2 ) 0-3 —, halo and C 1 -C 3 perfluoroalkyl where phenyl can be substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R 4 is —CHR 5 CO 2 H or —CH 2 -tetrazole where R 5 is H or benzyl; and n=0 or 1; or a pharmaceutically acceptable salt or ester form thereof.

  这项发明提供了新颖的化合物、药物组合物和治疗哺乳动物血栓性疾病的方法，这些化合物具有以下结构式：1其中：Ar为苯基、萘基、呋喃基、苯并呋喃基、吲哚基、吡唑基、噁唑基、芴基、苯基环烷烃，其中环烷烃可以是环丙基、环丁基、环戊基或环己基，Ar可以选择性地被1至3个来自C1-C6烷基、C1-C6烷氧基、羟基、苯基-(CH2)0-6—、苯基-(CH2)0-6O—、C3-C6环烷基、—(CH2)—C3-C6环烷基、卤素、C1-C3全氟烷基和C1-C3全氟烷氧基的基团取代；R1为氢、C1-C6烷基或苯基-(CH2)1-6—，其中苯基可以被C1-C6烷基、C1-C6烷氧基、卤素、三氟甲基或三氟甲氧基取代；R2和R3为H、C1-C6烷基、苯基-(CH2)0-3—、卤素和C1-C3全氟烷基，其中苯基可以被C1-C6烷基、C1-C6烷氧基、卤素、三氟甲基或三氟甲氧基取代；R4为—CHR5CO2H或—CH2-四唑基，其中R5为H或苄基；n=0或1；或其药用可接受的盐或酯形式。
• [EN] SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF<br/>[FR] PIPERIDINES SPIROCYCLIQUES UTILISEES COMME ANTAGONISTES DES MCH1 ET UTILISATIONS ASSOCIEES
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2004004714A1

  公开（公告）日：2004-01-15

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  这项发明涉及选择性拮抗黑色素浓缩激素-1（MCH1）受体的化合物。该发明提供了一种药物组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。该发明提供了一种通过结合本发明的化合物的治疗有效量和药学上可接受的载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明的化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种减少受试者体重的方法，包括向受试者投与本发明化合物的有效量以减少受试者体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投与本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。该发明还提供了一种治疗患有尿液失调的受试者的方法。